Background: Patients with B-cell chronic lymphocytic leukemia (CLL) with 17p deletion respond poorly to chemotherapy. This retrospective study evaluated the benefit of alemtuzumab monotherapy in unselected patients with advanced CLL in the various cytogenetic subgroups.
phase III study (CAM307) in chemonaive CLL patients [13] . Everyday use of alemtuzumab in clinical practice appears feasible, as substantiated by our recent retrospective report of 115 pretreated CLL patients from 25 Austrian centers [14] , demonstrating safety and efficacy profiles similar to those from prospective clinical trials [5] [6] [7] [8] [9] [10] [11] .
Recent data indicate that alemtuzumab is efficacious in terms of overall response rates (ORRs) and progression-free survival (PFS) even in CLL patients with 17p deletions [13, [15] [16] [17] [18] [19] , in whom conventional chemotherapy is usually ineffective. However, to date, only few data are available on the OS of CLL patients who were stratified according to cytogenetics and treated with alemtuzumab. In this article, we report the results of a retrospective study of 105 consecutive, unselected but cytogenetically categorized patients with advanced CLL, who were treated with alemtuzumab.
patients and methods study design and patients
This retrospective analysis was conducted using clinical data pertaining to treatment modalities, efficacy, and disease course collected from consecutive, unselected patients treated at 17 clinical centers in Austria, 2 centers in Southern Tyrol (Italy), and 1 in Brno (Czech Republic). All patients meeting the following criteria were included: (i) belonging to the known cytogenetic risk category, according to Döhner et al. [2] , as detected by FISH, (ii) undergoing alemtuzumab therapy for progressive, pretreated CLL requiring therapy. In this survey, alemtuzumab was initiated between 20 December 2001 and 19 December 2007. The last follow-up data available for this analysis was obtained on 20 January 2009, and the median observation time in this study was 22.5 months. The ethics committee at the Medical University of Innsbruck approved this study. The committee's recommendations concerning data management and security were followed. Forty-one patients analyzed in this study were also subjects of analysis in our previous study [14] . For these patients, a FISH result was available, and their survival data were updated.
cytogenetic analysis
For cytogenetic analysis, commercially available probes were used, targeting the characteristic CLL cytogenetic abnormalities. Cytogenetic categorization was carried out according to the hierarchical model of Döhner et al. [2] . The fact that cytogenetic analysis was done shortly before alemtuzumab therapy was important since it is known that the chance of clonal evolution with change of cytogenetic category increases with the duration of followup [20] . Analyses were carried out within a median of 2.3 months before starting alemtuzumab (range, 0-58.7 months; n = 105). In all patients with a FISH result obtained more than 1 year before the start of alemtuzumab therapy (n = 5), a second FISH analysis with an identical result after alemtuzumab therapy was available; thus, clonal evolution before the start of alemtuzumab therapy could be excluded. Definition of trisomy 12 required at least 5% of evaluated cells to exhibit this anomaly, for the 13q, 11q, and 17p deletions, the respective cut-off levels were 10% (cut-offs individually established in the different laboratories of contributing centers).
treatment schedule
Usually, the alemtuzumab dose had been escalated during the first week of therapy by intravenous (i.v.) administration of 3 mg on day 1, 10 mg on day 2, and 30 mg on day 3. Subsequent doses of 30 mg were intended to be administered by either i.v. or subcutaneous (s.c.) delivery thrice a week for an intended 12 weeks. However, policy regarding dose of alemtuzumab therapy and mode of application varied greatly and was left to the discretion of the clinicians at participating centers. Anti-infective prophylaxis with valacyclovir and trimethoprim-sulfamethoxazole was given according to accepted guidelines [21, 22] .
response evaluation
Patients who received at least one dose of alemtuzumab were assessable for efficacy and safety. Response or disease progression was evaluated according to the criteria of the National Cancer Institute Working Group [23] , after the last administration of alemtuzumab, at 2 months after the last dose, and thereafter in case of a delayed response. For documentation of complete response (CR), partial response (PR), or stable disease (SD), the result had to persist for at least 2 months. Bone marrow examination was required for documentation of CR. PFS was defined as time from first dose of alemtuzumab to disease progression or death, whichever occurred first. OS was measured from initiation of alemtuzumab therapy. Any toxic effect (defined as Common Toxicity Criteria grade ‡ 2) observed from the first administration of alemtuzumab until 2 months after last dose was considered treatment related. Finally, second malignancies at any time after alemtuzumab therapy were documented.
statistical considerations
Comparison of response rates between patient subgroups (based on the five cytogenetic categories and other baseline characteristics before alemtuzumab therapy) was carried out using Pearson's chi-square test. Event-related data (PFS and OS) were estimated using the Kaplan-Meier method, and comparison of outcomes between categorical subgroups was made using the log-rank test. Univariate analysis was used to determine which baseline characteristics were associated with PFS and OS. For those found to be significantly associated with PFS and OS, hazard ratios (HR) were calculated using the multivariate Cox regression analysis. The significance level was set at P < 0.05, in two-sided tests.
results

patient characteristics
A total of 105 consecutive, pretreated, otherwise unselected patients with CLL, treated with alemtuzumab monotherapy were included in this study. Patient demographics and baseline characteristics are detailed in Table 1 . Overall, 52% of patients had an unfavorable cytogenetic profile (17p or 11q deletion). The distribution of cytogenetic aberrations was comparable to that in a similar cohort of pretreated CLL patients analyzed by Lozanski et al. [15] and Wierda et al. [24] , indicating that our patient cohort was representative of a pretreated CLL population in terms of cytogenetic abnormalities.
All patients were pretreated with various regimens (median, two prior regimens, range 1-8). Notably, 22 patients (21%) received prior rituximab-containing chemoimmunotherapy (fludarabine and cyclophosphamide [FCR] ; cyclophosphamide, doxorubicin, vincristine and prednisone [R-CHOP]; and others), mostly in higher therapy line. A response was achieved in 8 of these 22 patients (36%). The majority of patients (59%) was fludarabine refractory, as defined previously [5, 23] . Twenty-six percent of patients had bulky lymphadenopathy (lymph nodes ‡ 5 cm). Although statistically not significant, it appeared that patients with 11q deletion had bulky lymphadenopathy more often than did the overall cohort of patients without 11q deletion (41% versus 22%; P = 0.077; Pearson's chi-square test), in line with previous observations [2, 25] . Alemtuzumab was given i.v. in 22 patients (21%) and s.c. in 81 patients (77%). In 60 out of 81 patients with s.c. administration, alemtuzumab was initially i.v. dose escalated. Mode of application was unknown in two patients. The median duration of alemtuzumab therapy was 9 weeks (range, 2-20 weeks), and the median cumulative dose administered was 493 mg (range, 26-1280 mg). In incremental analysis, we found that the different cytogenetic subgroups were balanced in the distribution of the following categorical parameters: gender, presence of splenomegaly, and refractoriness toward fludarabine (Pearson's chi-square test, data not shown). However, there was a trend showing that 17p-deleted patients were more frequently in higher stages (Rai 3 and 4) than were patients with other anomalies or normal interphase cytogenetics (80% versus 61%, P = 0.055). Moreover, there was no difference in the distribution of the following numeric parameters between the cytogenetic groups: hemoglobin, platelet and leukocyte counts, b2-microglobulin value, numbers of previous therapies, administered cumulative dose of alemtuzumab, and weeks on alemtuzumab therapy (analysis of variance test, data not shown).
response
Response to alemtuzumab therapy was evaluated in 101 patients. In the remaining four patients, response was not assessable due to premature death (n = 2), switch over to another therapy (n = 1), or data being unavailable (n = 1). The ORR was 43%, with CR and PR rates of 4% and 39%, respectively, which is in line with previous studies. The ORRs in the different cytogenetic categories are shown in Table 2 and were not statistically different when comparison was pooled over all strata (ORR per category; P = 0.355).
ORR in the 17p deletion category was 49%, which is in line with other studies [15, 16, 18] . The ORR in the 11q deletion category was only 30%, which is also similar to rates reported in other studies [15, 16] . SD, which was usually associated with substantial clinical benefit (e.g. normalization of blood values, decrease in B symptoms), was achieved in 24% of patients overall (Table 2) .
ORR was significantly lower in patients with splenomegaly (palpable or >13 cm by radiographic evaluation; P = 0.020), hepatomegaly (P = 0.007), and b2-microglobulin of >4 mg/l (P = 0.056; data not shown). Furthermore, ORR was significantly lower in patients with three or more prior lines of therapy (P = 0.006), anemia (P = 0.018), fludarabine-refractory CLL (P = 0.025), alemtuzumab treatment duration of <9 weeks (P = 0.001), and cumulative dose of alemtuzumab <500 mg (P <0.001; Table 2 ). Therapeutic responses in the cytogenetically defined subgroups differed according to the cumulative dose applied (<500 mg versus ‡500 mg). Statistically, the difference was significant only in CLL patients harboring trisomy 12 (Table 3 ). In the extraordinarily unfavorable cohort of CLL patients who were refractory to fludarabine and had 17p deletion (n = 20), ORR was 35% and was not different from corresponding patients with 11q deletion (n = 12, 33%) or with the good risk cytogenetic category (i.e. 13q deletion, normal interphase cytogenetics, trisomy 12; n = 30, ORR 33%).
progression-free survival
Disease progression of CLL was documented when the first signs of PD were registered. At the last update of data, 94 patients had disease progression, 4 patients died without disease progression, and 7 patients were alive and without disease progression. Median PFS after start of alemtuzumab therapy according to different clinical characteristics are detailed in Table 4 . The median PFS for all CLL patients was 7.0 months and ranged from 3.2 months in the 11q deletion cohort to 10.5 months for the trisomy 12 cohort (P = 0.006; Figure 1A ). [2] . The overall incidence of the four chromosomal anomalies (more than one abnormality per patient considered) was: 13q deletion, n = 47 (45%); trisomy 12, n = 24 (23%); 11q deletion, n = 22 (21%); and 17p deletion, n = 35 (33%).
In the prognostically unfavorable fludarabine-refractory patients, median PFS after start of alemtuzumab was 6.2 months. In CLL patients with 17p deletion (n = 20), 11q deletion (n = 12), and good risk cytogenetics (n = 30), PFS was 7.0, 2.7, and 6.2 months, respectively (P = 0.091). The median PFS in 17p-deleted patients did not differ statistically from the median PFS in patients with good risk cytogenetics, whereas 11q-deleted patients had significantly shorter PFS compared with patients with cytogenetically good risk CLL (P = 0.038; Figure 1B) .
In a multivariate Cox regression analysis, bicategorical pretreatment baseline characteristics that showed significance for PFS in the univariate analysis (Table 4) were included (namely bulky lymphadenopathy, cytogenetic risk group, b2-microglobulin), and it became evident that the following parameters were independent for shorter PFS: bulky lymphadenopathy (HR = 1.72, 95% confidence interval [CI] 1.01-2.94, P = 0.047) and cytogenetic poor-risk category (HR = 2.3; 95% CI 1.40-3.80, P = 0.001).
overall survival
Median OS after initiation of alemtuzumab therapy was 32.8 months in the total cohort of CLL patients. Median OS according to the cytogenetic category of Döhner et al. was not b Four patients were not assessable due to premature death (n = 2), switch over to another therapy (n = 1), or data being unavailable (n = 1). c All other patients.
CR, complete response, good risk group, 13q deletion, trisomy 12, and normal interphase cytogenetics (normal IC); NCI, National Cancer Institute; NE, not evaluable; ORR, overall response rate; PD, progressive disease, poor-risk group, 11q and 17p deletion categories; PR, partial response; SD, stable disease; i.v., intravenous; s.c., subcutaneous. reached for the cohort with trisomy 12 and was shortest for the cohort with 11q deletion, as outlined in Figure 2A and Table 4 .
In the 62 poor-prognosis patients who were characterized by refractoriness to fludarabine, median OS was 27.5 months. In patients with 17p deletion (n = 20), 11q deletion (n = 12), and [2] , the median PFS was 6.4 months for patients with 13q deletion (n = 19), 9.0 months for normal interphase cytogenetics (n = 17), 10.5 months for trisomy 12 (n = 14), 3.2 months for 11q deletion (n = 20), and 7.1 months for 17p deletion (n = 35), which was statistically different when comparison of PFS was pooled over all strata (P = 0.006). (B) Kaplan-Meier plot of patients with fludarabine-refractory CLL, who received alemtuzumab monotherapy, according to the cytogenetic grouping, as was carried out by Stilgenbauer et al [16] . Patients with 17p deletion (n = 20) had a median PFS of 7.0 months, those with good risk cytogenetics (n = 30; defined as those with 13q deletion, normal interphase cytogenetics, or trisomy 12) had a median PFS of 6.2 months. Patients with 11q deletion (n = 12), however, had a median PFS of only 2.7 months. There was only a statistical trend of difference when comparison of PFS was pooled over strata (P = 0.091); however, the pairwise comparison showed significantly shorter PFS for patients with 11q deletion as for those with good risk cytogenetics (P = 0.038).
original article Annals of Oncology good risk cytogenetics (n = 30), median OS was 19.2, 13.0 and 63.0 months, respectively (P = 0.085). The median OS in 17p-deleted patients did not differ statistically from that in patients with good risk cytogenetics, whereas 11q-deleted patients had significantly shorter OS compared with patients with good risk cytogenetics (P = 0.042; Figure 2B ). 
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In a multivariate Cox regression analysis considering significant pretreatment characteristics (i.e. anemia, number of previous lines of therapy, cytogenetic risk group, and b2-microglobulin; Table 4 ), independent risk factors for shorter OS were anemia (HR = 1.98, 95% CI 1.0-3.89, P = 0.049) and poorrisk cytogenetics (HR = 2.70, 95% CI 1.35-5.38, P = 0.005). [2] , the median OS was not reached among patients with trisomy 12 (n = 14). The median OS was 63.0 months for patients with 13q deletion (n = 19), 27.5 months for normal interphase cytogenetics (n = 17), 13.7 months for 11q deletion (n = 20), and 19.1 months for 17p deletion (n = 35). There was a trend of difference when comparison of OS was pooled over all strata (P = 0.071); however, the pairwise comparison showed significantly shorter OS for 11q-deleted patients and 17p-deleted patients when compared with trisomy 12 patients (P = 0.013 and P = 0.001, respectively). (B) OS is demonstrated in patients with fludarabine-refractory CLL, who received alemtuzumab monotherapy. Patients with 17p deletion (n = 20) had a median OS of 19.2; those with 11q deletion (n = 12), 13.0 months; and those with good risk cytogenetics (n = 30; 13q deletion, normal interphase cytogenetics, or trisomy 12), 63.0 months. There was a statistical trend of difference when comparison of OS was pooled over strata (P = 0.085); however, the pairwise comparison showed significantly shorter OS for 11q-deleted patients as for those with good risk cytogenetics (P = 0.042).
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In the 94 patients with disease progression during or after alemtuzumab therapy, disease progression and relapse presented primarily as increasing peripheral lymphocyte count in 34 patients (36%), progressive lymphadenopathy in 37 patients (39%), Richter's transformation in 9 patients (10%), and others (increasing lactate dehydrogenase, cachexia, and unspecified) in 12 patients (13%).
toxic effect
As detailed in Table 5 , toxic effects during therapy were neutropenia, thrombocytopenia, infections including cytomegaly virus reactivations, and hypersensitivity reactions. Second malignancies during follow-up after start of alemtuzumab therapy are listed in Table 5 . Death during therapy (or within 2 months after last alemtuzumab dose) occurred in six patients.
discussion
In our previous report [14] , we demonstrated in a nationwide survey in Austria that routine use of alemtuzumab in CLL patients was successful, in line with results from prospective studies [5] [6] [7] [8] [9] [10] [11] . Another retrospective study in British Columbia showed similar results [26] . Currently, it is a general trend to build up registries compiling data from center networks to be able to study efficacy and toxic effects in unselected patients beyond prospective clinical studies [27] . In the present study, we analyzed the impact of cytogenetic abnormalities on the clinical efficacy of alemtuzumab in a series of 105 patients. It must be noted that in a retrospective survey such as ours, patients differ from those in prospective studies. Therefore there are limitations to drawing definite conclusions. However, we were able to document that therapeutic results and toxic effect rates observed in prospective studies are translated nicely into the routine setting [14] . During data documentation, we were able to verify that the participating institutions started alemtuzumab therapy strictly along the proposed guidelines of administration and had their patients under tight clinical control. Generally, however, we realized that individualization of alemtuzumab schedule, predominantly through dose reductions, was frequently necessary, well in line with the observation of other researchers [26, 28] . Obviously, this did not substantially affect therapeutic efficacy [28, 29] . Thus, we are convinced that the results presented in our study reflect those achievable in CLL treatment in the routine setting. The data presented here may serve as a benchmark to other surveys on alemtuzumab use in CLL.
We found high ORR not only in patients with good risk cytogenetics such as 13q deletion and trisomy 12 but also in those in the bad risk category. Differences within the cytogenetic categories, such as the surprising finding that patients lacking any anomaly by 'standard' FISH CLL evaluation [2] had a relatively low ORR, may reflect a differential effect of alemtuzumab [13] , but results are contradictory [16] . In the study presented here, however, differences with respect to ORR between the cytogenetic categories did not reach statistical significance, in line with other studies [13, 16] . Of special interest is the fact that favorable response was seen in the poor-risk group with 17p deletion, which is comparable with published series with ORR between 40% and 50% [15, 16, 18] . In the largest study to date assessing alemtuzumab efficacy by cytogenetic group, the CAM307 study [13] , it was demonstrated that untreated CLL 
Annals of Oncology original article
patients with 17p deletions receiving alemtuzumab showed a remarkable response that was superior to the respective chlorambucil-treated patients (ORR 64% versus 20%, respectively; P = 0.08). In terms of response by alemtuzumab in 11q-deleted CLL, it seems to play a role whether or not patients were pretreated. In fact, ORR was 87% in therapy-naive patients in the CAM307 study [13] , whereas in pretreated patients, the achievable ORR is much lower: 27%, 30%, and 30%, respectively, as shown by Lozanski et al. [15] , Stilgenbauer et al. [16] , and our study. Thus, it appears that other therapeutic options in pretreated CLL with 11q deletion should be investigated. Recently, chemoimmunotherapy with rituximab, combined with FCR [30] or bendamustine [31] , yielded high response rates in pretreated CLL with 11q deletion. Furthermore, therapy with immunomodulating drugs, such as lenalidomide and flavopiridol, are under investigation and may be effective in treating patients with 11q deletion and bulky disease [32, 33] . Generally, there is an increasing role for allogeneic transplantation in high-risk CLL with curative potential for a minority of fit patients with a prognostically high-risk profile [34] .
PFS was favorable in CLL patients with 17q deletion, whereas patients with 11q deletion had a very short PFS of only 3.2 months (Table 4) . PFS rates in our study are generally shorter than those in the CAM307 study [13] . This is almost certainly due to the fact that all patients in our study were pretreated. In fact, the results of the prospective CAM307 study and this retrospective study are uniformly pointing to a differential efficacy of alemtuzumab in the various cytogenetic categories. In the subgroup of fludarabine-refractory patients, PFS was intermediate in patients with 17p deletion, whereas 11q-deleted patients had a significantly shorter PFS compared with the good risk group ( Figure 1B) . Thus, our results correspond to the recently published results of Stilgenbauer et al. in 17p-deleted, fludarabine-refractory patients [16] ; however, Stilgenbauer et al. [16] did not observe an inferior PFS in patients with 11q deletion, a difference that remains unexplained. It might be speculated that patients with 11q deletion in our cohort were characterized by additional, here unrecognized adverse characteristics such as complex karyotypes [35] .
OS appeared superior in CLL patients of the cytogenetic good risk group in comparison with patients with 17p and 11q deletions (Figure 2A) . However, the favorable OS of 19.1 months in 17p-deleted patients indicates a role for alemtuzumab especially in these patients who generally have a very poor OS following conventional chemotherapy. These rather favorable results may be partly attributed to the fact that re-treatment with alemtuzumab, carried out in nearly a third of all our patients, was efficacious, as observed in our recent analysis [36] . Taken together, these results indicate that alemtuzumab therapy in these traditionally very poor-risk patients is indeed able to shift them to an 'intermediate' prognosis, at least if they show a response to alemtuzumab. This seems to be the case also in the subgroup of fludarabinerefractory patients with 17p deletion, who showed a median OS of 19.2 months ( Figure 2B ). Our findings in patients receiving alemtuzumab with dual risk (fludarabine refractory and 17p deleted) adequately confirm the OS results recently published by Stilgenbauer et al. [16] . Again, there is a discrepancy in the patients with 11q deletion because there was a clearly superior OS in the cohort described by them [16] .
Of practical importance is our finding that the now widely applied s.c. route of alemtuzumab administration is just as effective, both in response and in survival, as the i.v. route, which is in agreement with other studies [16, 29] . Official approval for the s.c. route of administration should be an objective of the manufacturing company.
In conclusion, we have demonstrated that Döhner's cytogenetic risk categories [2] are useful for risk stratification in CLL patients undergoing treatment with alemtuzumab. But, we and others [16, 29] show that the OS difference between CLL with 11q deletion and 17p deletion disappeared. The encouraging efficacy of alemtuzumab treatment translates into an improved prognosis in 17p-deleted CLL patients in whom chemotherapy regimens usually fail. Obviously, alemtuzumab to a certain degree abrogates the adverse prognostic feature of 17p deletion in CLL. 
